Relationship Between Level of GPCR Autoantibodies and Cardiac Structure & Funtions Based on UCG and CMR

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05368584

Enrollment

Registered

2022-05-10

Start date

2022-05-07

Completion date

2022-12-31

Last updated

2022-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI

Keywords

STEMI, GPCR, PCI

Brief summary

This study is a prospective cohort study，we want to observe the changes of different cardiovascular antibody levels in STEMI patients undergoing emergency PCI;and combined with different cardiovascular antibody levels and various indicators, evaluate the impact of ischemia-reperfusion injury and prognosis in STEMI patients after emergency PCI.

Detailed description

This study mainly observed the changes of different cardiovascular antibody levels in STEMI patients undergoing emergency PCI by measuring autoantibodies; and the changes of autoantibodies in STEMI patients compared with coronary angiography-negative patients. At the same time, combined with different cardiovascular antibody levels and various indicators, the effect of ischemia-reperfusion injury and prognosis after emergency PCI in STEMI patients was evaluated. The correlation between autoantibody changes and imaging indicators in STEMI patients was evaluated by cardiac color Doppler ultrasound and CMR.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* STEMI patients meet the diagnostic criteria of Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2015); ②STMEI patients undergoing emergency PCI should undergo emergency PCI within 12 hours of onset at Beijing Friendship Hospital affiliated to Capital Medical University; ③ The selected patients were able to complete the MRI and STE examinations; ④ They agreed to be enrolled in the trial and signed the informed consent.

Exclusion criteria

* Past myocardial infarction or revascularization (PCI or CABG); ②Congestive heart failure LVEF\<40%; ③Atrial fibrillation; ④Renal insufficiency (GFR\<30 ml/min); disease; ⑥ rheumatic immune system disease; ⑦ malignant tumor; ⑧ claustrophobia; ⑨ contraindication to CMR;

Design outcomes

Primary

Measure	Time frame	Description
β1-AA, β2-AA, α1-AA, M2-AA and AT1-AA OD values	Admission Baseline	About 10ml of venous blood was collected on the second day of admission, serum was separated, and the OD values of β1-AA, β2-AA, α1-AA, M2-AA and AT1-AA were detected by ELISA.

Countries

China

Outcome results